secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagenic Therapeutics, Inc.new (PTIX)
CIK:        0001022899
Form:       8-K
Filed at:   2025-08-22T23:59:59+00:00
Accession:  0001641172-25-025274
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 4.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagenic: Nasdaq non-compliance for late 10-Q; auditor changed; PT00114 Phase I dosing complete
--------------------------------------------------------------------------------

- Dismissed MaloneBailey as auditor, engaged Green Growth CPAs as new independent auditor effective August 7, 2025.
- Received Nasdaq deficiency notice on Aug 20, 2025 due to late filing of Q2 2025 Form 10-Q; trading continues under PTIX.
- Expects to file overdue 10-Q soon; will submit compliance plan within 60 days if needed.
- Completed first dose injection for all subjects in multiple-dose portion of Phase I trial of PT00114; topline safety data expected by end of September.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022899/000164117225025274/0001641172-25-025274-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022899/000164117225025274/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-025274

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer